CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

PHASE4CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

CHF5993

Pressurized metered dose inhaler (pMDI) 2 inhalations bid

DRUG

CHF1535

Pressurized metered dose inhaler (pMDI) 2 inhalations bid

OTHER

Matched placebo

Pressurized metered dose inhaler (pMDI) 2 inhalations bid

Trial Locations (1)

PAREXEL International GmbH Early Phase Clinical Unit Berlin, Berlin-Spandau

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT05097014 - CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD | Biotech Hunter | Biotech Hunter